Metabolomics in rheumatoid arthritis: Advances and review

Lingxia Xu[1,2,3†], Cen Chang[1,2,3†], Ping Jiang[1,2,3], Kai Wei[1,2,3], Runrun Zhang[4], Yehua Jin[1,2], Jianan Zhao[1,2,3], Linshuai Xu[1,2], Yiming Shi[1,2,3], Shicheng Guo[5,6*] and Dongyi He[1,2,3*]

[1]Guanghua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, China, [2]Department of Rheumatology, Shanghai Guanghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, [3]Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China, [4]Department of Rheumatology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China, [5]Department of Medical Genetics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States, [6]Computation and Informatics in Biology and Medicine, University of Wisconsin-Madison, Madison, WI, United States

Rheumatoid arthritis (RA) is an autoimmune disease accompanied by metabolic alterations. The metabolic profiles of patients with RA can be determined using targeted and non-targeted metabolomics technology. Metabolic changes in glucose, lipid, and amino acid levels are involved in glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway, the arachidonic acid metabolic pathway, and amino acid metabolism. These alterations in metabolic pathways and metabolites can fulfill bio-energetic requirements, promote cell proliferation, drive inflammatory mediator secretion, mediate leukocyte infiltration, induce joint destruction and muscle atrophy, and regulate cell proliferation, which may reflect the etiologies of RA. Differential metabolites can be used as biomarkers for the diagnosis, prognosis, and risk prediction, improving the specificity and accuracy of diagnostics and prognosis prediction. Additionally, metabolic changes associated with therapeutic responses can improve the understanding of drug mechanism. Metabolic homeostasis and regulation are new therapeutic strategies for RA. In this review, we provide a comprehensive overview of advances in metabolomics for RA.

KEYWORDS

rheumatoid arthritis, metabolomics, pathogenesis, medicine, biomarkers

Abbreviations: RA, rheumatoid arthritis; ACPA, anti-citrullinated protein antibody; RF, rheumatoid factor; NMR, nuclear magnetic resonance; LC-MS, liquid chromatography-mass spectrometry; TCA, tricarboxylic acid; PPP, pentose phosphate pathway; AA, arachidonic acid; HIF-1α, hypoxia inducible factor-1α; IL, interleukin; MMP9, matrix metalloproteinase 9; 5-HETE, 5-hydroxyeicosatetraenoic acid; CIA, collagen-induced arthritis; FLS, fibroblast-like synoviocyte; OGPC, 1-oleoyl-sn-glycero-3-phosphocholine; HC, healthy controls; CCL, C-C chemokine ligand; SF, synovial fluid; TNF-α, tumor necrosis factor-α; PsA, psoriatic arthritis; DMARDs, disease-modifying antirheumatic drugs; L1, lipid methyls; AUC, area under the curve; ILD, Interstitial lung disease; DAS28-CRP, disease activity score that considers 28 joints with C-reactive protein; MTX, methotrexate; TNFi, TNF-α inhibitor; NLRP3, nucleotide binding domain and leucine-rich repeat pyrin 3 domain.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized by progressive synovial inflammation. The development of RA is associated with susceptibility genes, epigenetic modification, and the environment (1). Immune cells, synovial cells, and cytokines are involved in joint inflammation (2). Abnormal cellular and humoral immune responses lead to the development of autoantibodies. However, the key biological pathways driving the initial autoimmunity remain unclear (3). Patients with RA can be classified according to the presence or absence of antibodies. Although seronegative RA may be associated with T cell disorders, the pathogenesis is not well-understood (4). RA is diagnosed based on clinical symptoms and laboratory indicators, such as the major markers anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) (5). However, RF and ACPA have also been detected in other autoimmune diseases, such as systemic lupus erythematosus and systemic sclerosis (6, 7). Furthermore, seronegative RA patients have a high rate of misdiagnosis. The accurate diagnosis, prognosis, and risk prediction of RA remain difficult because of the limited number of powerful biomarkers. The pathological changes of RA synovial membrane are the formation of synovial pannus and infiltration of immune cells. High demands on energy requirements and biosynthetic precursors, suggesting that metabolic changes are a fundamental disease mechanism. In recent decades, studies have focused on the pathogenesis and discovery of new biomarkers using novel and high-precision techniques, particularly metabolomics (8, 9).

Metabolomics is an evolving science that has followed the development of genomics, transcriptomics, and proteomics. Metabolites, by contrast, are the end result of interactions among genes, RNA and proteins that better reflect the current state of an individual, showing the potential as biomarkers. Meanwhile, more and more metabolites involved in the pathogenesis of diseases have been discovered. Glutamate can stimulate tumor growth, survival, and proliferation by activating phosphoinositide 3-kinase/Akt pathways (10). Sphingosine-1-phosphate is important molecular players in metabolic diseases (11). Lactate is not only the end product of glycolysis but also acting as signalling molecule both in chronically inflamed tissues and in cancerous tissues (12). These studies emphasize the intrinsic physiological activity of metabolites and provide new significance for the value of metabolomics. Small-molecule metabolites in the tissues or body fluids (blood, urine, synovial fluid) were identified by using nuclear magnetic resonance (NMR) spectroscopy, liquid chromatography-mass spectrometry (LC-MS), and gas chromatography-mass spectrometry metabolomics (13). They help to identify differential metabolites between patients with RA and other individuals, study the pathogenesis of RA, and screen for new

diagnostic and prognostic markers. We provide a comprehensive overview of recent progress in metabolomics research of RA.

Metabolomics reveals the pathogenesis of RA

RA is a complex disease caused by dysfunction in multiple metabolic pathways. Glycolysis, the tricarboxylic acid (TCA) cycle, the pentose phosphate pathway (PPP), the arachidonic acid (AA) metabolic pathway, and amino acid metabolism have been widely studied for their roles in RA (14, 15). The levels of intermediate metabolites in these metabolic pathways were shown to be increased or decreased compared with those in healthy controls (HC) (16–18). Metabolites changes in RA (Table 1) promote inflammation and the immune response directly or indirectly in the pathogenesis (Figure 1).

A critical pathological feature of RA is the hypoxic microenvironment of the synovial tissues (35). In the absence of sufficient oxygen, prolyl-4-hydroxylases enzymes fail to hydroxylate the proline residues in the oxygen-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α), thus preventing it's ubiquitination or proteasomal degradation by von-Hippel-Lindau protein, resulting in stabilization of HIF-1α (36). HIF-1α is transcription factor, which plays a crucial role in glucose metabolism. It can increase the expression of the downstream genes, like glucose transporter 1, and enzymes involved in glycolysis, such as hexokinase 2, phosphofructokinase-1, and pyruvate kinase M2, to promote glucose transport into cells and glycolysis (37–40). The inflammatory response stimulates an increase in the energy demand. Glucose metabolism *via* glycolysis enables cells to produce ATP when oxygen levels are low to generate the energy required by RA cells (41). Remarkably, glycolysis-derived metabolites were recently found to be critical for immune cell infiltration and inflammatory pathway activation (42). Pyruvate, the final product of glycolysis, shows higher levels in the muscle in patients with RA compared to that in HC, suggesting that glycolysis is enhanced in RA (19). Pyruvate shows a strong angiogenic activity by increasing the expression of vascular endothelial growth factor and fibroblast growth factor receptor-2 (43).

Pyruvate dehydrogenase complex and pyruvate carboxylase decarboxylate pyruvate to form acetyl-coenzyme A and oxaloacetate, respectively, which enter the TCA cycle in the mitochondria. The mitochondrial ultrastructure was damaged under hypoxia conditions, indicating the breakdown of cellular bioenergetics, which affected the metabolism in TCA cycle (44). Intermediates of the TCA cycle such as α-ketoglutaric acid and citrate typically show decreased levels, whereas succinate is upregulated in RA (20–22). α-Ketoglutaric acid regulates the balance between M1 and M2 macrophage polarization, induces the secretion of interleukin (IL)-10 from T cells, and alleviates

TABLE 1 Metabolites changes in rheumatoid arthritis.

The first author	Cases	Species	Sample type	Platform	Up-regulated metabolites	Down-regulated metabolites	Ref.
Yang, X.Y.	RA(n=25) vs HC (n=10)	human	SF	GC-MS	lactic acid	glucose	9
Srivastava, N.K.	CIA rat (n=5) vs Ctrl rat (n=5)	rat	joint	1H-NMR	lactate, alanine, branched-chain amino acids, creatinine	choline, glycerophosphocholine	14
Anderson, J.R.	RA(n=14) vs OA (n=10)	human	SF	1H-NMR	acetate, acetylated-saccharides, glycine, isoleucine, leucine, methionine, sarcosine, threonine	3-hydroxybutyrate, 2-hydroxybutyrate, 3-hydroxyisovaleratecitrate, acetylcholine, adenosine, alanine, asparagine, citrate, creatinine, glucose, glutamine, glycerol, guanidoacetate, histidine, mannose, mobile-lipid, myoinositol, n-acetylamino acid, proline, pyruvate, sn-glycero-3-phosphocholine, taurine, tyrosine, valine	15
Zhou, J.	RA(n=33) vs HC (n=32)	human	serum	GC-MS	pyruvate	branched-chain amino acids, leucine, isoleucine, valine, threonine, alanine, methionine	17
Huffman, K.M.	RA(n=51) vs HC (n=51)	human	muscle	LC-MS	pyruvate		19
Alonso, A.	IMID (n=1210) vs HC (n=100)	human	urine	1H-NMR		citrate	20
He, Z.	RA(n=15) vs HC (n=15)	human	plasma	GC-MS	thymidine, uridine	glycine, proline, 2-ketoglutaric acid, chenodeoxycholic acid, ursodeoxycholic acid	21
Kim, S.	RA (n=13) vs non-RA [AS (n=7), BD (n=5), gout (n=13)]	human	SF	GC-MS	succinate, octadecanol, asparagine, terephthalate, salicylaldehyde, glutamine, citrulline, tyrosine, uracil, lysine, ribitol, tryptophan, xylose, ribose	isopalmitic acid, glycerol, myristic acid, palmitoleic acid, hydroxylamine, ethanolamine	22
Ahn, J.K.	RA FLS vs OA FLS	patient-derived cell	FLS	GC-MS	fructose-6-phosphate, glucose-6-phosphate	galactose, glucose, glutamine, methionine sulfoxide, oxoproline, threonine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine	23
Kim, J.	RA FLS vs OA FLS	patient-derived cell	FLS	LC-MS	adenine	glutamic acid, proline	24
	RA iPSCs vs OA iPSCs	patient-derived iPSCs	iPSCs	LC-MS	nicotinamide, 4-methoxychalcone, lysoPCs		
Jiang, M.	RA(n=27) vs HC (n=60)	human	serum	GC-MS, LC-MS	lactic acid, dihydroxyfumaric acid, aspartic acid, glyceraldehyde, homoserine	4,8-Dimethylnonanoyl carnitine	25
Ding, X.	CIA rat (n=6) vs Ctrl rat (n=6)	rat	serum	LC-MS	TXB2, 12(S)-HHTrE, PGE2, 12(S)-HETE, 12(S)-HEPE	Lyso-PE(18:2), Lyso-PE(20:4), Lyso-PC(22:5)	26
Wang, N	CIA rat (n=8) vs Ctrl rat (n=9)	rat	joint	LC-MS	PGE2, PGD2, LTB4, LTE4, 15-HETE, 12-HETE, 5-HETE, arachidonic acid	TXA2	27
Jónasdóttir, H.S.	RA(n=24) vs OA (n=10)	human	SF	LC-MS	15-HETE, 6-trans-LTB4, 20-OH-LTB4, 17-HDoTE		28
He, M.	CIA mouse (n=10) vs	mouse	plasma	LC-MS	12-HEPE, 13-HDoHE, 14-HDoHE, 8-HETE, 12-HETE,	methionine, homocysteine, threonine, proline, alanine,valine, cystathionin, lysine, glycylglycine, serine, asparagine, cysteine,	29

(Continued)

TABLE 1 Continued

The first author	Cases	Species	Sample type	Platform	Up-regulated metabolites	Down-regulated metabolites	Ref.
	Ctrl mouse (n=10)				10-HDoHE, 13,14-dihydro-PGF2a	tryptophan, glutamine, glutamine, leucine, gamma-glutamylalanine, PGE3, 9-hydroxyoctadecadienoic acid, 9,10-dihydroxy-9Z-octadecenoic acid	
He, Z.	RA(n=27) vs HC (n=27)	human	plasma	GC-MS		cysteine, glutamine, citric acid	30
Liu, Y	AIA rat (n=10) vs Ctrl rat (n=10)	rat	plasma	LC-MS	glutamate, arginine, methionine	proline, valine, tyrosine, phenylalanine, leucine, glycine, tryptophan, histidine, threonine	31
He, M.	CIA mouse (n=9) vs Ctrl mouse (n=10)	mouse	plasma	LC-MS	methylcysteine, o-phosphoethanolamine	methionine, homocysteine, threonine, proline, alanine, cystathionine, valine, glycylglycine, lysine, serine, asparagine, cysteine, tryptophan	32
Takahashi, S.	RA FLS vs OA FLS	patient-derived cell	FLS	GC-MS, CE-MS		glucose, glutamine, glutamate, lactate	33
Su, J.	RA(n=240) vs HC (n=69)	human	plasma	LC-MS		1-oleoyl-sn-glycero-3-phosphocholine,1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine, glycerophosphocholine, l-alanine	34

RA, Rheumatoid arthritis; HC, healthy controls; SF, synovial fluid; GC-MS, gas chromatography-mass spectrometry; CIA, collagen-induced arthritis; Ctrl, control; NMR, nuclear magnetic resonance; OA, osteoarthritis; LC-MS, liquid chromatography-mass spectrometry; IMID, Immune-mediated inflammatory diseases, including Crohns' disease, ulcerative colitis, RA, psoriatic arthritis, psoriasis, systemic lupus erythematosus; BD, Behçet's disease; FLS, Fibroblast-like synoviocytes; iPSCs, induced pluripotent stem cells; ;TXB2, thromboxane B2; 12(S)-HHTrE, 12S-hydroxy-5Z, 8E, 10E-heptadecatrienoic acid; PGE2, prostaglandin E2; 12 (S)-HETE, 12S-hydroxyeicosatetraenoic acid; 12 (S)-HEPE, 12S-hydroxypentaenoic acid; LTB4, leukotrienes B4; HDoTE, hydroxydocosatetraenoic acid; AIA, adjuvant-induced arthritis; CE-MS, capillary electrophoresis-mass spectrometry.

inflammation (45, 46). Succinate can activate immune cells and sustain IL-1β production (47). Citrate is negatively correlated with C-reactive protein (CRP) (48). The significance of altered TCA pathways in RA is currently being investigated, but a previous study showed that disruption of redox is associated with immunity and inflammation (49).

Glucose 6-phosphate from glycolysis enters the PPP to produce ribose 5-phosphate and nicotinamide adenine dinucleotide phosphate, which drive anabolic metabolism and biomass production (50). Enhanced PPP and activated glycolysis-related metabolic pathways in RA contribute to rapid cell proliferation in the RA synovium (23, 24).

Pyruvate can be converted into lactate, which is significantly elevated in RA (9, 14, 25). Accumulated lactate can mediate the inhibition of CD4+ T cell viability in RA, promote M2 polarization, and induce IL-17 expression by activating transducer and activator of transcription 3 in CD4+T cells (51, 52).

AA can be released from membrane phospholipids under hypoxia and inflammatory activation. AA increases matrix metalloproteinase 9 (MMP9) secretion and expression (53). MMPs can degrade the extracellular matrix, which causes joint destruction (54). As metabolites of AA, prostaglandin E2, thromboxane A2, leukotriene-B4, 5-hydroxyeicosatetraenoic acid (5-HETE), 8-HETE, 12-HETE, 15-HETE, and 12(S)-HETE were upregulated in the serum of a collagen-induced arthritis (CIA) rat model (26, 27). These eicosanoids oxidized by

AA are lipids that mediate the inflammatory response and inflammatory cell infiltration (55, 56). Leukotriene-B4 can initiate and amplify polymorphonuclear neutrophil chemotaxis and increase the severity of acute inflammation (57). Prostaglandin E2 plays an important role in immune system inflammation, synovial hyperplasia, leukocyte infiltration, and cytokine secretion such as IL-23-dependent IL-17 production (58). 15-HETE can increase the expression of MMP2 and MMP9 to promote angiogenesis (59). The activities of 5-lipoxygenase and 15-lipoxygenase, which affect the metabolic pathway of AA, were higher in RA compared with that in osteoarthritis (28).

Amino acid metabolism disorders often occur in patients with RA. Proline, tryptophan, cysteine, and glutamine levels are inconsistent between RA and control group (29, 30). Levels of aspartic acid, citrulline, and arginine, which are involved in the urea cycle, are increased in RA (22, 25, 31). Arginine, proline, and glutamine can be converted to a-ketoglutaric acid to participate in the TCA cycle. Increased consumption of glutamine is associated with T cell proliferation (60). The interaction between citrulline and human leukocyte antigen has important effects on ACPA expression (61). In addition to characterizing inflammatory and immune function disorders, muscle expenditure is associated with metabolic abnormalities in RA, particularly amino acid metabolism. Compared to the control group, levels of several amine metabolites (methionine, homocysteine, threonine, proline, alanine, cystathionine, valine, and glycylglycine) were significantly reduced in CIA mice, which

FIGURE 1

Alternations of metabolic pathways participate in the pathogenesis of rheumatoid arthritis. In the hypoxia microenvironment, HIF-1α promotes the expression of glucose transporter 1 and activation of hexokinase 2, phosphofructokinase-1, and pyruvate kinase M2 in glycolysis. Glucose transported across the cell membranes by glucose transporter 1 then converted to pyruvate and generates two molecules of ATP. Glucose 6-phosphate from glycolysis enters the PPP to produce ribose 5-phosphate and nicotinamide adenine dinucleotide phosphate. Pyruvate is transformed into acetyl-coenzyme A and oxaloacetate and enters the TCA cycle in the mitochondria. AA can be derived from membrane phospholipids in hypoxia and inflammatory environments. AA oxidized to thromboxanes and prostaglandins such as prostaglandin E2 by cyclooxygenase, or leukotrienes and HETEs by lipoxygenase promotes leukocyte infiltration. Arginine, proline, and glutamine can be converted into α-ketoglutaric acid and participate in the TCA cycle. Metabolite changes in RA can promote cytokine secretion, increasing the expression of vascular endothelial growth factor, fibroblast growth factor receptor-2, MMP9, MMP2, and activated signal transducer and activator of transcription phosphorylation along with leukocyte infiltration. Red (up) arrow indicates up-regulated metabolites and green (down) arrow indicates down-regulated metabolites. The figure was drawn by using Figdraw. AA, Arachidonic acid; α-KG, α- Ketoglutarate; ATP, Adenosine Triphosphate; FGFR-2, Fibroblast Growth Factor Receptor 2; G6P, Glucose 6 Phosphatase; GLUT, Glucose Transporters; HIF-1, Hypoxia Inducible Factor-1; HK2, Hexokinase 2; IL-1β, Interleukin-1β; IL-10, Interleukin-10; IL-17, Interleukin-17; LDHl, Lactate Dehydrogenase; LOX, lipoxygenase; LTs, Leukotrienes; MMP2, Matrix Metalloproteinases2; MMP9, Matrix Metalloproteinases9; NADPH, Nicotinamide Adenine Dinucleotide Phosphate; PC, pyruvate carboxylase; PDC, pyruvate dehydrogenase complex; PEG2, Prostaglandin E2; PFK1, Phosphofructokinase-1; PKM2, Pyruvate Kinase M2; PPP, Pentose Phosphate Pathway; R5P, ribulose 5-phosphate; STAT3, Signal Transducer and Activator of Transcription 3; TCA, Tricarboxylic Acid; TXs, Thromboxane; VEGF, Vascular Endothelial Growth Factor.

may be related to muscle atrophy (29, 32). In contrast, high concentrations of ornithine, glycine, proline, aspartate, and arginine in the muscle were related to skeletal muscle dysfunction (19). Metabolomics analysis also revealed increased metabolism of the non-essential amino acid glutamine in RA-fibroblast-like synoviocytes (FLS). Glutamine deprivation reduced the proliferation of RA-FLS, suggesting that glutamine plays an important role in regulating the proliferation of these cells (33).

Other metabolites may also mediate the secretion of inflammatory cytokines and are involved in the inflammatory pathway of RA. 1-Oleoyl-*sn*-glycero-3-phosphocholine (OGPC) levels were lower in patients with RA compared with that in HC based on non-target metabolomics analysis. OGPC can downregulate the level of IL-6 in the plasma and further affect the downstream Janus kinase signaling pathway (34). C-C chemokine ligand (CCL)-20 was found to be increased significantly in the RA synovial fluid (SF) under hypoxia conditions, which was mainly mediated by carnitine (62).

Formate, propylene glycol, glutamine, lysine alanine, glucose, and serine dimethylamine in the serum were negatively correlated with synovial tumor necrosis factor-α (TNF-α) (63).

Although metabolomics has improved the understanding of the pathogenesis of RA, some studies have reported inconsistent results (64–66). For instance, 1D-NMR was used to determine the concentrations of glucose and lactate in the supernatants and cell extracts, which showed similar results between the RA and uninflamed control group (67). However, the concentrations of glucose were decreased when in RA when the control group are HC or OA (9, 15). Branched-chain amino acids were upregulated in the joint tissues of CIA rats but downregulated in the SF of patients with RA (14, 17).The metobolic in tissue or cells may represents metabolic characteristics of specific position, which may cause different trends in studies. Additionally, the concentrations of metabolites between the blood and urine in CIA rats differ (18). In addition to the above reasons, the other underlying reason for inconsistent changes in metabolites in different studies requires further study.

Despite these discrepant results, metabolomics can further expand our understanding of RA. Activation of glycolysis, the PPP pathway, and AA metabolism and perturbations in the TCA cycle and amino acid metabolism can meet the energy supply in the pathological environment of RA and provide materials for immune cell and synovial cell proliferation. The diversity in metabolites explains the mechanisms of inflammatory cell infiltration, cytokines accumulation, angiogenesis, bone destruction, and muscle atrophy. In addition to targeted and untargeted metabolomics in RA, integrating proteomics, transcriptomics, and genomics can help reveal the specific disease pathogenesis (68). Using metabolomics approaches, changes in metabolites can be evaluated to identify the molecular characteristics of RA and detailed the pathogenesis (20, 69).

Identifying biomarkers of RA using metabolomics

According to current classification criteria, the diagnosis of RA includes the type and number of affected joints, concentrations of RF and ACPA in serology analysis, acute-phase reactants, and duration of symptoms (70). It is particularly challenging to differentiate seronegative RA and other diseases with overlapping symptoms, such as osteoarthritis and psoriatic arthritis (PsA). New biomarkers for differentiating RA, especially seronegative RA, and other inflammatory arthritis are urgently needed. Patients would also benefit from the identification of biomarkers for diagnosing different complications.

RA is treated using trial-and-error approach, in which disease-modifying antirheumatic drugs (DMARDs) are key therapeutic drugs. According to treatment guidelines, when DMARDs fail, biological agents are recommended (71). Patients are more likely to suffer adverse effects when the effects of a treatment are uncertain, supporting the need for prognostic biomarkers.

The metabolic processes of RA differ between healthy individuals and those with other inflammatory or rheumatic diseases, even when their clinical features are similar (72–74). Serum metabolite and lipid concentrations were calculated using ^{1}H single-pulse NMR of samples from patients with seronegative RA and PsA. Age, sex, lipid polyunsaturated allylic methylenes/lipid methyls (L1), lipid α-methylenes/L1, lipid aliphatic chain/L1, alanine, succinate, and creatine phosphate are found to be predictors in diagnostic models with an area under the curve (AUC) of 0.845 (8). The concentrations of lactic acid and glucose were detected in the SF from patients with inactive RA, patients with active RA, and normal subjects. The lactic acid concentration in SF was elevated whereas that of glucose was decreased in RA. The lactic acid and glucose levels show potential as biomarkers for active RA. Lactic acid showed 96%

sensitivity and 85% specificity. Glucose showed 84% sensitivity and 95% specificity (9). In another study, blood metabolites were analyzed among HC, RA, and PsA subjects. Fifty-two differential metabolites, evaluated in a subsequent validation test to distinguish patients with RA from HC, showed a sensitivity of 81% and specificity of 67% (75). The levels of plasma nucleotides (UTP, ATP, GDP, and ADP) in patients with RA were elevated. However, the levels of plasma nucleotides in systemic lupus erythematosus and PsA did not significantly differ, compared with those of controls in association tests. These results indicate the disease specificity of plasma nucleotides in RA, revealing their potential as clinical biomarkers for RA, particularly for seronegative RA (76). Serum samples from patients with RA, primary Sjögren's syndrome, and HC were analyzed using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry. 4-Methoxyphenylacetic acid, L-phenylalanine, and L-leucine were screened as specific biomarkers to distinguish patients with RA from those with PsA and HC (77). Differential metabolites between RA and HC have been detected in several studies, but their use as diagnostic markers requires validation in large cohorts (78–81).

Additionally, there have been exciting advances in the use of diagnostic markers for patients with RA-related complications. Compared to those in interstitial lung disease (ILD) (-) RA, the serum concentrations of decanoic acid and morpholine were lower, whereas the concentration of glycerol was higher in ILD (+) RA. These three metabolites with an AUC of 0.919 can be used as markers to distinguish ILD in RA (82). Metabolomics methods were applied to identify biomarkers of renal damage in RA. Five specific markers (stachydrine, 2-phenylethanol glucuronide, lysoPC (18:2) b, lysoPC (16:0) a, lysoPC (18:3) b) were identified as potential biomarkers for renal damage (83). Higher plasma asymmetric dimethyl-l-arginine concentrations were inversely correlated with the log-transformed reactive hyperemia index and significantly associated with endothelial dysfunction (84),which may be associated with RA-related cardiovascular disease.

CRP, erythrocyte sedimentation (ESR), disease activity score using CRP (DAS28-CRP), and DAS28-ESR are commonly used to evaluate inflammation and disease activity in RA (85). One limitation of assessing disease activity using DAS28 is the subjectivity of the analysis of painful of joint counts (86, 87). CRP secretion is largely induced by IL-6 and IL-1, which were interrupt by IL-6 or IL-1 inhibitor (88). The used of biological agent like tocilizumab may lead to a decrease in CRP, which does not necessarily imply a decrease in disease activity (89). In recent years, a lot of researches have been devoted to discover the metabolites to reflect and predict disease activity and inflammation. Fifty-one metabolites were significantly associated with the disease activity score, which were significantly associated with DAS28-CRP (90). The concentration of the tryptophan metabolite, kynurenine in RA-SF was significantly lower than that in osteoarthritis.

Kynurenine was negatively correlated with the CRP concentration, which is a dependable biomarker for RA (91). Twelve metabolites (glycocyamine, indol-3-lactate, β-alanine, asparagine, citrate, cyano-L-alanine, leucine, nicotinamide, citrulline, methionine, oxoproline, and salicylaldehyde) were significantly correlated with DAS28-ESR (92). Elevated levels of lactate, acetylated glycoprotein, cholesterol, and unsaturated lipids and a decreased level of high-density lipoprotein show potential as biomarkers of disease severity (93). The current high-throughput metabolomics studies were limited in still rely on CRP, ESR and DAS28 to define RA inflammation and disease activity. Nevertheless, these metabolites show potential for disease activity and inflammation monitoring.

A large proportion of patients show a poor response to DMARDs or biological agents (94, 95). Drug treatment can alter serum metabolite levels in RA (96–99). Additionally, the metabolic profiles differ between patients who respond and do not respond to treatment (100). Identifying biomarkers of the drug response before administration would greatly reduce treatment costs. Metabolite profiles were examined prior to treatment initiation with methotrexate (MTX) in 82 patients with early RA, which revealed homocysteine, glycerol-3-phosphate, and 1,3-/2,3-DPG as models for predicting the response to MTX with an AUC of 0.81 (95% CI: 0.72–0.91) (101). The plasma level of N-methylisoleucine in MTX-responsive mice was significantly lower than that in nonresponsive mice, indicating its potential as a therapeutic biomarker (102). Baseline urine metabolism profiles were discriminated to differentiate responders from non-responders to TNF-α inhibitor (TNFi) (infliximab and etanercept) therapy with a sensitivity of 88.9% and specificity of 85.7% (103). A multivariate diagnostic model (adjusted for age, ACPA positivity, and interleukins), 3-hydroxybutyrate, and phenylalanine correctly predicted non-responders and responders in 77.1% of cases (104). Orthogonal projections to latent structures discriminant analysis showed good discrimination of responders and moderate responders to etanercept when the plasma metabolic profile of patients with RA was analyzed after 6 months of etanercept treatment (105). The S-plot and variable importance in projection scores calculated using the same method revealed metabolites that contributed to the differences in responders. Five metabolites (glycerol 3-phosphate, betonicine, N-acetylalanine, hexanoic acid, and taurine) are potential predictors of TNFi respondents. Three metabolites (3-aminobutyric acid, citric acid, and quinic acid) show potential as predictors of the response to abatacept (106). After 6 months of TNFi therapy, two different metabolic profiles separated good responders from non-responders, and carbohydrate derivates (D-glucose, D-fructose, sucrose, and maltose) emerged as determinants of the therapeutic response. However, the prediction model based only on the most significant metabolites lacks sufficient discrimination (107). Combining metabolites and clinical

models can improve the accuracy of identifying non-responsive patients. Serum samples from patients with RA were measured using targeted LC-MS platforms, which showed that combining metabolites with clinical parameters exhibited reasonable predictive abilities for differentiating TNFi responders and non-responders (108). Twenty-four metabolites may respond to the biological DMARDs analyzed using NMR spectroscopy. Compared with levels in those who did not respond, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylneuraminic acid levels were responders before and after three months of biological DMARD treatment (109). A combined model containing 16 clinical baseline parameters and 4 metabolites was built to predict the response to TNFi therapy. The model accurately discriminated good- and non-responders (108).

Metabolomics reveals the drug mechanism of action

The biochemical basis of the role of DMARDs in RA remains controversial (110). As previously described, metabolic changes in patients with RA are involved in the disease pathogenesis. Metabolite analysis can further improve the understanding of the efficacy and potential biochemical mechanisms of drug therapy.

Plasma metabolites were identified in HC and MTX-treated patients with RA at baseline and after 16 weeks of treatment. MTX partially corrected the levels of triglycerides and fatty acids and normalized plasma metabolism in patients with RA (111). Exposure of the K562 human erythroblastoid cell line to MTX increased levels of 76 and decreased levels of 68 metabolites. The key metabolic pathways associated with the pharmacological activity of MTX include folate-related metabolites, nucleotides, amino acids, and carbohydrates. However, mechanistic studies are needed to define how MTX affects these pathways (112). MTX can downregulate the activation of nuclear factor kappa-light-chain-enhancer of activated B cells, nucleotide-binding domain, and leucine-rich repeat pyrin 3 domain/caspase-1 inflammatory pathways; reduce the levels of cytokines; and regulate inflammation-related metabolic networks (arachidonic acid, linoleic acid, and sphingolipid metabolism). The direct or indirect role of the MTX-mediated metabolome and inflammatory pathways requires further validation (113). ^{1}H NMR-based lipid/metabolomics was used to investigate changes in lipid metabolites in the serum from patients with RA treated with Janus kinase inhibitors. The levels of omega-3 polyunsaturated fatty acids and docosahexaenoic acid (DHA) were elevated. A decrease in pain was significantly associated with the elevate of DHA levels (114). The results have invited our speculation, whether intake of exogenous DHA also relieves pain in RA? Chronic prednisolone therapy is associated with a

lower asymmetric dimethyl-l-arginine concentration, suggesting that long-term glucocorticoid administration can restore endothelial function (115). Traditional Chinese medicine is also widely used to treat RA, but its mechanism of action requires further investigation. Metabolomics is a powerful approach for understanding the mechanism of traditional Chinese medicine formulations (116–119).

Limitations and outlook

The heterogeneity of patients with RA is an important factor affecting the accuracy of the results of studies with small sample sizes (120). The RA metabolome results require further validation using large sample, multicenter cohort data. The inconsistent medication regimen in participants, accompanied by metabolic disorders (diabetes, fatty liver, adiposis), body mass index, and whether samples were collected before or after meals, are important factors influencing metabolic disturbances (121–123). Thus, the patients recruited for these studies should be carefully considered and meet stringent criteria. Because of the complexity of metabolites, sample processing is necessary (124, 125). Additionally, ongoing effort is required to improve the coverage of extremely low-abundance metabolites.

Overall, biomarker screening using metabolomics can improve the accuracy of diagnosis and prognosis, without the need for subjective experience. Metabolomics studies of seronegative RA are important for examining the disease pathogenesis and screening for biomarkers. Additionally, further studies of other rheumatoid immune diseases are needed to demonstrate the effectiveness of the diagnosis biomarkers. Metabolic changes that participate in the pathogenesis of RA can provide a mechanism and rationale for treatment administration, such as glucose deprivation or glycolytic inhibitors (126, 127). Novel sensitive therapeutics can be developed to target key enzymes in metabolic pathways. With the progression of multi-omics technology, integrative analysis of metabolomics with proteomics, transcriptome, genomics, and 16S rRNA gene sequencing can provide insight into RA (128, 129) and lead to precision medicine.

Author contributions

Writing—original draft preparation, LXX and CC. Writing—review and editing, RZ, YJ, PJ, KW, LSX, YS. Project administration, DH and SG. Funding acquisition, DH. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *New Engl J Med* (2011) 365(23):2205–19. doi: 10.1056/NEJMra1004965

2. Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. *Cells* (2020) 9(4):880. doi: 10.3390/cells9040880

3. Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. *J Autoimmun* (2020) 110:102400. doi: 10.1016/j.jaut.2019.102400

4. Pratt AG, Isaacs JD. Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best practice & research. *Clin Rheumatol* (2014) 28(4):651–9. doi: 10.1016/j.berh.2014.10.016

5. Martinez-Prat L, Nissen MJ, Lamacchia C, Bentow C, Cesana L, Roux-Lombard P, et al. Comparison of serological biomarkers in rheumatoid arthritis

and their combination to improve diagnostic performance. *Front In Immunol* (2018) 9:1113. doi: 10.3389/fimmu.2018.01113

6. Ball EMA, Tan AL, Fukuba E, McGonagle D, Grey A, Steiner G, et al. A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status. *Rheumatol (Oxford England)* (2014) 53(10):1835–43. doi: 10.1093/rheumatology/keu215

7. Riccardi A, Martinroche G, Contin-Bordes C, Avouac J, Gobeaux C, Cauvet A, et al. Erosive arthritis autoantibodies in systemic sclerosis. *Semin Arthritis rheumatism* (2022) 52:151947. doi: 10.1016/j.semarthrit.2021.11.013

8. Souto-Carneiro M, Tóth L, Behnisch R, Urbach K, Klika KD, Carvalho RA, et al. Differences in the serum metabolome and lipidome identify potential

biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. *Ann Rheumatic Dis* (2020) 79(4):499–506. doi: 10.1136/annrheumdis-2019-216374

9. Yang XY, Zheng KD, Lin K, Zheng G, Zou H, Wang JM, et al. Energy metabolism disorder as a contributing factor of rheumatoid arthritis: A comparative proteomic and metabolomic study. *PLoS One* (2015) 10(7): e0132695. doi: 10.1371/journal.pone.0132695

10. Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. *Clin Cancer Res* (2012) 18(16):4240–6. doi: 10.1158/1078-0432.CCR-11-1217

11. Green CD, Maceyka M, Cowart LA, Spiegel S. Sphingolipids in metabolic disease: The good, the bad, and the unknown. *Cell Metab* (2021) 33(7):1293–306. doi: 10.1016/j.cmet.2021.06.006

12. Certo M, Tsai C-H, Pucino V, Ho P-C, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. *Nat Rev Immunol* (2021) 21(3):151–61. doi: 10.1038/s41577-020-0406-2

13. Muthubharathi BC, Gowripriya T, Balamurugan K. Metabolomics: Small molecules that matter more. *Mol Omics* (2021) 17(2):210–29. doi: 10.1039/D0MO00176G

14. Srivastava NK, Sharma S, Sharma R, Sinha N, Mandal SK, Sharma D, et al. Metabolic fingerprinting of joint tissue of collagen-induced arthritis (CIA) rat: *In vitro*, high resolution NMR (nuclear magnetic resonance) spectroscopy based analysis. *Excli J* (2018) 17:257–72. doi: 10.17179/excli2017-938

15. Anderson JR, Chokesuwattanaskul S, Phelan MM, Welting TJM, Lian L-Y, Peffers MJ, et al. H NMR metabolomics identifies underlying inflammatory pathology in osteoarthritis and rheumatoid arthritis synovial joints. *J Proteome Res* (2018) 17(11):3780–90. doi: 10.1021/acs.jproteome.8b00455

16. Kosinska MK, Liebisch G, Lochnit G, Wilhelm J, Klein H, Kaesser U, et al. Sphingolipids in human synovial fluid–a lipidomic study. *PLoS One* (2014) 9(3): e91769. doi: 10.1371/journal.pone.0091769

17. Zhou J, Chen J, Hu C, Xie Z, Li H, Wei S, et al. Exploration of the serum metabolite signature in patients with rheumatoid arthritis using gas chromatography-mass spectrometry. *J Pharm Biomed Anal* (2016) 127:60–7. doi: 10.1016/j.jpba.2016.02.004

18. Cheng X, Xu T, Pi Z, Liu S, Song F, Liu Z, et al. A wide-targeted urinary and serum metabolomics strategy reveals the effective substance of the Wu-tou decoction. *J Sep Sci* (2020) 43(4):727–35. doi: 10.1002/jssc.201900678

19. Huffman KM, Jessee R, Andonian B, Davis BN, Narowski R, Huebner JL, et al. Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability. *Arthritis Res Ther* (2017) 19 (1):12. doi: 10.1186/s13075-016-1215-7

20. Alonso A, Julià A, Vinaixa M, Domènech E, Fernández-Nebro A, Cañete JD, et al. Urine metabolome profiling of immune-mediated inflammatory diseases. *BMC Med* (2016) 14(1):133. doi: 10.1186/s12916-016-0681-8

21. He Z, Luo Q, Liu Z, Gong L. Extensive evaluation of sample preparation workflow for gas chromatography-mass spectrometry-based plasma metabolomics and its application in rheumatoid arthritis. *Anal Chim Acta* (2020) 1131:136–45. doi: 10.1016/j.aca.2020.06.029

22. Kim S, Hwang J, Xuan J, Jung YH, Cha HS, Kim KH. Global metabolite profiling of synovial fluid for the specific diagnosis of rheumatoid arthritis from other inflammatory arthritis. *PLoS One* (2014) 9(6):e97501. doi: 10.1371/journal.pone.0097501

23. Ahn JK, Kim S, Hwang J, Kim J, Kim KH, Cha HS. GC/TOF-MS-based metabolomic profiling in cultured fibroblast-like synoviocytes from rheumatoid arthritis. *Joint Bone Spine* (2016) 83(6):707–13. doi: 10.1016/j.jbspin.2015.11.009

24. Kim J, Kang SC, Yoon NE, Kim Y, Choi J, Park N, et al. Metabolomic profiles of induced pluripotent stem cells derived from patients with rheumatoid arthritis and osteoarthritis. *Stem Cell Res Ther* (2019) 10(1):319. doi: 10.1186/s13287-019-1408-5

25. Jiang M, Chen T, Feng H, Zhang Y, Li L, Zhao A, et al. Serum metabolic signatures of four types of human arthritis. *J Proteome Res* (2013) 12(8):3769–79. doi: 10.1021/pr400415a

26. Ding X, Hu J, Li J, Zhang Y, Shui B, Ding Z, et al. Metabolomics analysis of collagen-induced arthritis in rats and interventional effects of oral tolerance. *Anal Biochem* (2014) 458:49–57. doi: 10.1016/j.ab.2014.04.035

27. Wang N, Zhao X, Wang W, Peng Y, Bi K, Dai R. Targeted profiling of arachidonic acid and eicosanoids in rat tissue by UFLC-MS/MS: Application to identify potential markers for rheumatoid arthritis. *Talanta* (2017) 162:479–87. doi: 10.1016/j.talanta.2016.10.065

28. Jónasdóttir HS, Brouwers H, Kwekkeboom JC, van der Linden HMJ, Huizinga T, Kloppenburg M, et al. Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans. *Osteoarthritis Cartilage* (2017) 25(7):1150–60. doi: 10.1016/j.joca.2017.01.018

29. He M, van Wijk E, van Wietmarschen H, Wang M, Sun M, Koval S, et al. Spontaneous ultra-weak photon emission in correlation to inflammatory metabolism and oxidative stress in a mouse model of collagen-induced arthritis. *J Photochem Photobiol B* (2017) 168:98–106. doi: 10.1016/j.jphotobiol.2016.12.036

30. He Z, Liu Z, Gong L. Biomarker identification and pathway analysis of rheumatoid arthritis based on metabolomics in combination with ingenuity pathway analysis. *Proteomics* (2021) 21(11-12):e2100037. doi: 10.1002/pmic.202100037

31. Liu Y, Xie Y. Metabolomics approach to the exploration of amino acids metabolism changes associated with disease progression in a rat model of adjuvant-induced arthritis. *J Environ Pathol Toxicol Oncol* (2021) 40(4):43–52. doi: 10.1615/JEnvironPatholToxicolOncol.2021039409

32. He M, Harms AC, van Wijk E, Wang M, Berger R, Koval S, et al. Role of amino acids in rheumatoid arthritis studied by metabolomics. *Int J Rheum Dis* (2019) 22(1):38–46. doi: 10.1111/1756-185X.13062

33. Takahashi S, Saegusa J, Sendo S, Okano T, Akashi K, Irino Y, et al. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis. *Arthritis Res Ther* (2017) 19(1):76. doi: 10.1186/s13075-017-1283-3

34. Su J, Li S, Chen J, Jian C, Hu J, Du H, et al. Glycerophospholipid metabolism is involved in rheumatoid arthritis pathogenesis by regulating the IL-6/JAK signaling pathway. *Biochem Biophys Res Commun* (2022) 600:130–5. doi: 10.1016/j.bbrc.2022.02.003

35. Quiñonez-Flores CM, González-Chávez SA, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritis. *J Biomed Sci* (2016) 23(1):62. doi: 10.1186/s12929-016-0281-0

36. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. *Acta Pharm Sin* (2015) 5(5):378–89. doi: 10.1016/j.apsb.2015.05.007

37. Xu O, Li X, Qu Y, Liu S, An J, Wang M, et al. Regulation of glucose transporter protein-1 and vascular endothelial growth factor by hypoxia inducible factor 1α under hypoxic conditions in hep-2 human cells. *Mol Med Rep* (2012) 6 (6):1418–22. doi: 10.3892/mmr.2012.1075

38. Cao L, Wang M, Dong Y, Xu B, Chen J, Ding Y, et al. Circular RNA circRNF20 promotes breast cancer tumorigenesis and warburg effect through miR-487a/HIF-1α/HK2. *Cell Death Dis* (2020) 11(2):145. doi: 10.1038/s41419-020-2336-0

39. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. *Cell* (2011) 145(5):732–44. doi: 10.1016/j.cell.2011.03.054

40. Hu L, Zeng Z, Xia Q, Liu Z, Feng X, Chen J, et al. Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1α/PFKFB3/PFK1 pathway. *Life Sci* (2019) 239:116966. doi: 10.1016/j.lfs.2019.116966

41. Weyand CM, Goronzy JJ. Immunometabolism in early and late stages of rheumatoid arthritis. *Nat Rev Rheumatol* (2017) 13(5):291–301. doi: 10.1038/nrrheum.2017.49

42. Li W, Xu M, Li Y, Huang Z, Zhou J, Zhao Q, et al. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer. *J Trans Med* (2020) 18(1):92. doi: 10.1186/s12967-020-02267-2

43. Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW, Kim YJ, et al. Angiogenic activity of pyruvic acid in *in vivo* and *in vitro* angiogenesis models. *Cancer Res* (2001) 61(8):3290–3. doi: 10.1016/S0165-4608(00)00403-9

44. Wang Q, Wang P, Qin Z, Yang X, Pan B, Nie F, et al. Altered glucose metabolism and cell function in keloid fibroblasts under hypoxia. *Redox Biol* (2021) 38:101815. doi: 10.1016/j.redox.2020.101815

45. Liu S, Yang J, Wu Z. The regulatory role of -ketoglutarate metabolism in macrophages. *Mediators Inflammation* (2021) 2021:5577577. doi: 10.1155/2021/5577577

46. Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, et al. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. *Cell Metab* (2020) 32(3):447–456.e6. doi: 10.1016/j.cmet.2020.08.004

47. Mills E, O'Neill LAJ. Succinate: a metabolic signal in inflammation. *Trends In Cell Biol* (2014) 24(5):313–20. doi: 10.1016/j.tcb.2013.11.008

48. Jutley GS, Sahota K, Sahbudin I, Filer A, Arayssi T, Young SP, et al. Relationship between inflammation and metabolism in patients with newly presenting rheumatoid arthritis. *Front Immunol* (2021) 12:676105. doi: 10.3389/fimmu.2021.676105

49. McGettrick AF, O'Neill LA. How metabolism generates signals during innate immunity and inflammation. *J Biol Chem* (2013) 288(32):22893–8. doi: 10.1074/jbc.R113.486464

50. Yang Z, Shen Y, Oishi H, Matteson EL, Tian L, Goronzy JJ, et al. Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. *Sci Trans Med* (2016) 8(331):331ra38. doi: 10.1126/scitranslmed.aad7151

51. Pucino V, Certo M, Bulusu V, Cucchi D, Goldmann K, Pontarini E, et al. Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4(+) T cell metabolic rewiring. *Cell Metab* (2019) 30(6):1055–1074.e8. doi: 10.1016/j.cmet.2019.10.004

52. Zhang A, Xu Y, Xu H, Ren J, Meng T, Ni Y, et al. Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. *Theranostics* (2021) 11(8):3839–52. doi: 10.7150/thno.53749

53. Solakivi T, Kunnas T, Kärkkäinen S, Jaakkola O, Nikkari ST, et al. Arachidonic acid increases matrix metalloproteinase 9 secretion and expression in human monocytic MonoMac 6 cells. *Lipids In Health Dis* (2009) 8:11. doi: 10.1186/1476-511X-8-11

54. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. *Front In Bioscience J Virtual Library* (2006) 11:529–43. doi: 10.2741/1817

55. Wang T, Fu X, Chen Q, Patra JK, Wang D, Wang Z, et al. Arachidonic acid metabolism and kidney inflammation. *Int J Mol Sci* (2019) 20(15):3683. doi: 10.3390/ijms20153683

56. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol* (2008) 8 (5):349–61. doi: 10.1038/nri2294

57. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. *Nat Immunol* (2001) 2 (7):612–9. doi: 10.1038/89759

58. Samuels JS, Holland L, López M, Meyers K, Cumbie WG, McClain A, et al. Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4 T-cell development during rheumatoid arthritis. *Inflammation Res* (2018) 67(7):589–96. doi: 10.1007/s00011-018-1153-8

59. Liu Y, Zhang H, Yan L, Du W, Zhang M, Chen H, et al. MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells. *J Mol Cell Cardiol* (2018) 121:36–50. doi: 10.1016/j.yjmcc.2018.06.006

60. Sener Z, Cederkvist FH, Volchenkov R, Holen HL, Skålhegg BS. T Helper cell activation and expansion is sensitive to glutaminase inhibition under both hypoxic and normoxic conditions. *PLoS One* (2016) 11(7):e0160291. doi: 10.1371/journal.pone.0160291

61. Ting YT, Petersen J, Ramarathinam SH, Scally SW, Loh KL, Thomas R, et al. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. *J Biol Chem* (2018) 293 (9):3236–51. doi: 10.1074/jbc.RA117.001013

62. Rodgers LC, Cole J, Rattigan KM, Barrett MP, Kurian N, McInnes IB, et al. The rheumatoid synovial environment alters fatty acid metabolism in human monocytes and enhances CCL20 secretion. *Rheumatol (Oxford)* (2020) 59(4):869–78. doi: 10.1093/rheumatology/kez378

63. Narasimhan R, Coras R, Rosenthal SB, Sweeney SR, Lodi A, Tiziani S, et al. Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis. *Arthritis Res Ther* (2018) 20(1):164. doi: 10.1186/s13075-018-1655-3

64. Bouzit L, Malspeis S, Sparks JA, Cui J, Karlson EW, Yoshida K, et al. Assessing improved risk prediction of rheumatoid arthritis by environmental, genetic, and metabolomic factors. *Semin Arthritis Rheum* (2021) 51(5):1016–22. doi: 10.1016/j.semarthrit.2021.07.006

65. Bondt A, Wuhrer M, Kuijper TM, Hazes JM, Dolhain RJ. Fab glycosylation of immunoglobulin G does not associate with improvement of rheumatoid arthritis during pregnancy. *Arthritis Res Ther* (2016) 18(1):274. doi: 10.1186/s13075-016-1172-1

66. Maciejewski M, Sands C, Nair N, Ling S, Verstappen S, Hyrich K, et al. Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. *Sci Rep* (2021) 11(1):7266. doi: 10.1038/s41598-021-86729-7

67. Falconer J, Pucino V, Clayton SA, Marshall JL, Raizada S, Adams H, et al. Spontaneously resolving joint inflammation is characterised by metabolic agility of fibroblast-like synoviocytes. *Front Immunol* (2021) 12:725641. doi: 10.3389/fimmu.2021.725641

68. You S, Koh JH, Leng L, Kim W-U, Bucala R. The tumor-like phenotype of rheumatoid synovium: Molecular profiling and prospects for precision medicine. *Arthritis Rheumatol (Hoboken N.J.)* (2018) 70(5):637–52. doi: 10.1002/art.40406

69. Blackmore D, Li L, Wang N, Maksymowych W, Yacyshyn E, Siddiqi ZA, et al. Metabolomic profile overlap in prototypical autoimmune humoral disease: a comparison of myasthenia gravis and rheumatoid arthritis. *Metabolomics* (2020) 16(1):10. doi: 10.1007/s11306-019-1625-z

70. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European league against rheumatism collaborative initiative. *Arthritis Rheumatism* (2010) 62(9):2569–81. doi: 10.1002/art.27584

71. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. *Lancet (London England)* (2010) 376(9746):1094–108. doi: 10.1016/S0140-6736(10)60826-4

72. Carlson AK, Rawle RA, Wallace CW, Adams E, Greenwood MC, Bothner B, et al. Global metabolomic profiling of human synovial fluid for rheumatoid arthritis biomarkers. *Clin Exp Rheumatol* (2019) 37(3):393–9.

73. Nieminen P, Hämäläinen W, Savinainen J, Lehtonen M, Lehtiniemi S, Rinta-Paavola J, et al. Metabolomics of synovial fluid and infrapatellar fat pad in patients with osteoarthritis or rheumatoid arthritis. *Inflammation* (2022) 45 (3):1101–17. doi: 10.1007/s10753-021-01604-x

74. Miltenberger-Miltenyi G, Cruz-Machado AR, Saville J, Conceição VA, Calado Â, Lopes I, et al. Increased monohexosylceramide levels in the serum of established rheumatoid arthritis patients. *Rheumatol (Oxford)* (2020) 59(8):2085–9. doi: 10.1093/rheumatology/kez545

75. Madsen RK, Lundstedt T, Gabrielsson J, Sennbro CJ, Alenius GM, Moritz T, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. *Arthritis Res Ther* (2011) 13(1):R19. doi: 10.1186/ar3243

76. Kishikawa T, Maeda Y, Nii T, Arase N, Hirata J, Suzuki K, et al. Increased levels of plasma nucleotides in patients with rheumatoid arthritis. *Int Immunol* (2021) 33(2):119–24. doi: 10.1093/intimm/dxaa059

77. Li J, Che N, Xu L, Zhang Q, Wang Q, Tan W, et al. LC-MS-based serum metabolomics reveals a distinctive signature in patients with rheumatoid arthritis. *Clin Rheumatol* (2018) 37(6):1493–502. doi: 10.1007/s10067-018-4021-6

78. Yousri NA, Bayoumy K, Elhaq WG, Mohney RP, Emadi SA, Hammoudeh M, et al. Large Scale metabolic profiling identifies novel steroids linked to rheumatoid arthritis. *Sci Rep* (2017) 7(1):9137. doi: 10.1038/s41598-017-05439-1

79. Zabek A, Swierkot J, Malak A, Zawadzka I, Deja S, Bogunia-Kubik K, et al. Application of (1)H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis. *J Pharm BioMed Anal* (2016) 117:544–50. doi: 10.1016/j.jpba.2015.10.007

80. Lee YJ, Mun S, Lee YR, Lee S, Kwon S, Kim D, et al. A discovery of screening markers for rheumatoid arthritis by liquid chromatography mass spectrometry: A metabolomic approach. *Int J Rheum Dis* (2020) 23(10):1353–62. doi: 10.1111/1756-185X.13935

81. Shi W, Deng Y, Zhao C, Xiao W, Wang Z, Xiong Z, et al. Integrative serum metabolomic analysis for preventive effects of yaobitong capsule in adjuvant-induced rheumatoid arthritis rat based on RP/HILIC-UHPLC-Q-TOF MS. *Anal Biochem* (2022) 637:114474. doi: 10.1016/j.ab.2021.114474

82. Furukawa H, Oka S, Shimada K, Okamoto A, Hashimoto A, Komiya A, et al. Serum metabolomic profiling in rheumatoid arthritis patients with interstitial lung disease: A case-control study. *Front Med (Lausanne)* (2020) 7:599794. doi: 10.3389/fmed.2020.599794

83. Song L, Yin Q, Kang M, Ma N, Li X, Yang Z, et al. Untargeted metabolomics reveals novel serum biomarker of renal damage in rheumatoid arthritis. *J Pharm BioMed Anal* (2020) 180:113068. doi: 10.1016/j.jpba.2019.113068

84. Erre GL, Mangoni AA, Passiu G, Bassu S, Castagna F, Carru C, et al. Comprehensive arginine metabolomics and peripheral vasodilatory capacity in rheumatoid arthritis: A monocentric cross-sectional study. *Microvasc Res* (2020) 131:104038. doi: 10.1016/j.mvr.2020.104038

85. Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, et al. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. *Front In Med* (2018) 5:185. doi: 10.3389/fmed.2018.00185

86. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B, et al. Disease activity score-28 values differ considerably depending on patient's pain perception and sex. *J Rheumatol* (2007) 34(12):2382–7.

87. Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Non-inflammatory causes of pain in patients with rheumatoid arthritis. *Curr Rheumatol Rep* (2016) 18(6):30. doi: 10.1007/s11926-016-0581-0

88. Black S, Kushner I, Samols D. C-reactive protein. *J Biol Chem* (2004) 279 (47):48487–90. doi: 10.1074/jbc.R400025200

89. Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. *Scandinavian J Rheumatol* (2017) 46(2):87–94. doi: 10.1080/03009742.2016.1183039

90. Hur B, Gupta VK, Huang H, Wright KA, Warrington KJ, Taneja V, et al. Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity. *Arthritis Res Ther* (2021) 23(1):164. doi: 10.1186/s13075-021-02537-4

91. Kang KY, Lee SH, Jung SM, Park SH, Jung BH, Ju JH, et al. Downregulation of tryptophan-related metabolomic profile in rheumatoid arthritis synovial fluid. *J Rheumatol* (2015) 42(11):2003–11. doi: 10.3899/jrheum.141503

92. Ahn JK, Kim J, Cheong YE, Kim KH, Cha HS, et al. Variation in the synovial fluid metabolome according to disease activity of rheumatoid arthritis. *Clin Exp Rheumatol* (2020) 38(3):500–7.

93. Lauridsen MB, Bliddal H, Christensen R, Danneskiold-Samsøe B, Bennett R, Keun H, et al. 1H NMR spectroscopy-based interventional metabolic phenotyping:

a cohort study of rheumatoid arthritis patients. *J Proteome Res* (2010) 9(9):4545–53. doi: 10.1021/pr1002774

94. Ochi S, Saito K, Mizoguchi F, Kato S, Tanaka Y. Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: A retrospective cohort study. *Arthritis Res Ther* (2020) 22(1):41. doi: 10.1186/s13075-020-2122-5

95. Nair N, Plant D, Verstappen SM, Isaacs JD, Morgan AW, Hyrich KL, et al. Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. *Rheumatol (Oxford England)* (2020) 59(6):1364–71. doi: 10.1093/rheumatology/kez411

96. Alolga RN, Opoku-Damoah Y, Alagpulinsa DA, Huang FQ, Ma G, Chavez Leon M, et al. Metabolomic and transcriptomic analyses of the anti-rheumatoid arthritis potential of xylopic acid in a bioinspired lipoprotein nanoformulation. *Biomaterials* (2021) 268:120482. doi: 10.1016/j.biomaterials.2020.120482

97. Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: Insights from systems biology. *Arthritis Res Ther* (2018) 20(1):230. doi: 10.1186/s13075-018-1729-2

98. Fu J, Cuppen BV, Welsing PM, van Wietmarschen H, Harms AC, Berger R, et al. Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment. *Inflammopharmacology* (2016) 24(6):397–402. doi: 10.1007/s10787-016-0284-1

99. Fan Z, Ross RP, Stanton C, Hou B, Zhao J, Zhang H, et al. Lactobacillus casei CCFM1074 alleviates collagen-induced arthritis in rats *via* balancing Treg/Th17 and modulating the metabolites and gut microbiota. *Front Immunol* (2021) 12:680073. doi: 10.3389/fimmu.2021.680073

100. Wang Z, Chen Z, Yang S, Wang Y, Yu L, Zhang B, et al. (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. *Exp Ther Med* (2012) 4(1):165–71. doi: 10.3892/etm.2012.567

101. Gosselt HR, Muller IB, Jansen G, van Weeghel M, Vaz FM, Hazes JMW, et al. Identification of metabolic biomarkers in relation to methotrexate response in early rheumatoid arthritis. *J Pers Med* (2020) 10(4):271. doi: 10.3390/jpm10040271

102. Salamoun YM, Polireddy K, Cho YK, Medcalf MR, Funk RS. Methotrexate disposition, anti-folate activity, and metabolomic profiling to identify molecular markers of disease activity and drug response in the collagen-induced arthritis mouse model. *Metabolites* (2021) 12(1):24. doi: 10.3390/metabo12010024

Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. *Arthritis Rheum* (2013) 65(6):1448–56. doi: 10.1002/art.37921

104. Murillo-Saich JD, Diaz-Torne C, Ortiz MA, Coras R, Gil-Alabarse P, Pedersen A, et al. Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: An exploratory study. *Metabolomics* (2021) 17(9):74. doi: 10.1007/s11306-021-01822-2

105. Priori R, Casadei L, Valerio M, Scrivo R, Valesini G, Manetti C, et al. ¹H-NMR-Based metabolomic study for identifying serum profiles associated with the response to etanercept in patients with rheumatoid arthritis. *PLoS One* (2015) 10(11):e0138537. doi: 10.1371/journal.pone.0138537

106. Takahashi S, Saegusa J, Onishi A, Morinobu A, et al. Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients. *Rheumatol (Oxford)* (2019) 58(12):2153–61. doi: 10.1093/rheumatology/kez199

107. Tatar Z, Migne C, Petera M, Gaudin P, Lequerre T, Marotte H, et al. Variations in the metabolome in response to disease activity of rheumatoid arthritis. *BMC Musculoskelet Disord* (2016) 17(1):353. doi: 10.1186/s12891-016-1214-5

108. Cuppen BV, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen AC, et al. Exploring the inflammatory metabolomic profile to predict response to TNF-α inhibitors in rheumatoid arthritis. *PLoS One* (2016) 11(9):e0163087. doi: 10.1371/journal.pone.0163087

109. Dudka I, Chachaj A, Sebastian A, Tański W, Stenlund H, Gröbner G, et al. Metabolomic profiling reveals plasma GlycA and GlycB as a potential biomarkers for treatment efficiency in rheumatoid arthritis. *J Pharm BioMed Anal* (2021) 197:113971. doi: 10.1016/j.jpba.2021.113971

110. Chan ESL, Cronstein BN. Methotrexate–how does it really work? *Nat Rev Rheumatol* (2010) 6(3):175–8. doi: 10.1038/nrrheum.2010.5

111. Medcalf MR, Bhadbhade P, Mikuls TR, O'Dell JR, Gundry RL, Funk RS, et al. Plasma metabolome normalization in rheumatoid arthritis following initiation of methotrexate and the identification of metabolic biomarkers of efficacy. *Metabolites* (2021) 11(12):824. doi: 10.3390/metabo1120824

112. Funk RS, Singh RK, Becker ML. Metabolomic profiling to identify molecular biomarkers of cellular response to methotrexate *in vitro*. *Clin Transl Sci* (2020) 13(1):137–46. doi: 10.1111/cts.12694

113. Pang Z, Wang G, Ran N, Lin H, Wang Z, Guan X, et al. Inhibitory effect of methotrexate on rheumatoid arthritis inflammation and comprehensive metabolomics analysis using ultra-performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-Q/TOF-MS). *Int J Mol Sci* (2018) 19(10):2894. doi: 10.3390/ijms19102894

114. Chang CK, Chen PK, Chen CC, Chang SH, Chen CH, Chen DY, et al. Increased levels of omega-3 fatty acids and DHA are linked to pain reduction in rheumatoid arthritis patients treated with janus kinase inhibitors. *Nutrients* (2021) 13(9):3050. doi: 10.3390/nu13093050

115. Radhakutty A, Mangelsdorf BL, Drake SM, Rowland A, Smith MD, Mangoni AA, et al. Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomics. *Atherosclerosis* (2017) 266:190–5. doi: 10.1016/j.atherosclerosis.2017.10.004

116. Li R, Guo LX, Li Y, Chang WQ, Liu JQ, Liu LF, et al. Dose-response characteristics of clematis triterpenoid saponins and clematichinenoside AR in rheumatoid arthritis rats by liquid chromatography/mass spectrometry-based serum and urine metabolomics. *J Pharm BioMed Anal* (2017) 136:81–91. doi: 10.1016/j.jpba.2016.12.037

117. Linghang Q, Yiyi X, Guosheng C, Kang X, Jiyuan T, Xiong L, et al. Effects of atractylodes oil on inflammatory response and serum metabolites in adjuvant arthritis rats. *BioMed Pharmacother* (2020) 127:110130. doi: 10.1016/j.biopha.2020.110130

118. Liu Y, Zhang B, Cai Q. Study on the pharmacodynamics and metabolomics of five medicinal species in atractylodes DC. on rats with rheumatoid arthritis. *BioMed Pharmacother* (2020) 131:110554. doi: 10.1016/j.biopha.2020.110554

119. Shan J, Peng L, Qian W, Xie T, Kang A, Gao B, et al. Integrated serum and fecal metabolomics study of collagen-induced arthritis rats and the therapeutic effects of the zushima tablet. *Front Pharmacol* (2018) 9:891. doi: 10.3389/fphar.2018.00891

120. Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG. Treatment of rheumatoid arthritis: Unraveling the conundrum. *J Autoimmun* (2015) 65:1–18. doi: 10.1016/j.jaut.2015.10.003

121. Morris C, O'Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, et al. The relationship between BMI and metabolomic profiles: A focus on amino acids. *Proc Nutr Soc* (2012) 71(4):634–8. doi: 10.1017/S0029665112000699

122. Arneth B, Arneth R, Shams M. Metabolomics of type 1 and type 2 diabetes. *Int J Mol Sci* (2019) 20(10):2467. doi: 10.3390/ijms20102467

123. Pang Y, Kartsonaki C, Lv J, Millwood IY, Fairhurst-Hunter Z, Turnbull I, et al. Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study. *Am J Clin Nutr* (2022) 115(3):799–810. doi: 10.1093/ajcn/nqab392

124. Brouwers H, von Hegedus JH, van der Linden E, Mahdad R, Kloppenburg M, Toes R, et al. Hyaluronidase treatment of synovial fluid is required for accurate detection of inflammatory cells and soluble mediators. *Arthritis Res Ther* (2022) 24(1):18. doi: 10.1186/s13075-021-02696-4

125. Fu J, Schoeman JC, Harms AC, van Wietmarschen HA, Vreeken RJ, Berger R, et al. Metabolomics profiling of the free and total oxidised lipids in urine by LC-MS/MS: application in patients with rheumatoid arthritis. *Anal Bioanal Chem* (2016) 408(23):6307–19. doi: 10.1007/s00216-016-9742-2

126. Wang H, Zhang N, Fang K, Chang X. 2-Deoxy-D-glucose alleviates collagen-induced arthritis of rats and is accompanied by metabolic regulation of the spleen and liver. *Front Immunol* (2021) 12:713799. doi: 10.3389/fimmu.2021.713799

127. de Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis. *Front In Immunol* (2019) 10:1743. doi: 10.3389/fimmu.2019.01743

128. Chen Y, Ma C, Liu L, He J, Zhu C, Zheng F, et al. Analysis of gut microbiota and metabolites in patients with rheumatoid arthritis and identification of potential biomarkers. *Aging (Albany NY)* (2021) 13(20):23689–701. doi: 10.18632/aging.203641

129. Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. *Nat Commun* (2018) 9(1):2755. doi: 10.1038/s41467-018-05044-4